Navigation Links
Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
Date:2/19/2008

velopment, members of the management and scientific teams will be present at the upcoming FDA Anti-Infectives Advisory Committee meeting discussing non-inferiority margins in CAP clinical trials scheduled for April 1 and 2, 2008 in Maryland. The Company will hold an investor conference call on April 3, 2008 after the completion of the FDA Anti-Infectives Advisory Committee to provide management's viewpoints and reflections on the deliberations.

In an effort to re-confirm the regulatory pathway for cethromycin in CAP after the Anti-Infectives Advisory Committee meeting is completed, Advanced Life Sciences has requested and established a meeting on April 7, 2008 with the FDA to discuss the anticipated NDA submission in CAP. The Company will conduct a conference call with investors on April 10, 2008 to discuss the outcome of the April 7th meeting with the FDA.

Summary of Upcoming Events:

-- April 3 -- conference call to provide management's understanding of

and reflections on the discussions of the FDA

Anti-Infectives Advisory Committee meeting

-- April 10 -- conference call to discuss the outcome of the Company's

one-on-one meeting with the FDA

The Company will issue a press release with the time and dialing instructions for each call in advance.

Conference Call Details:

The Company is hosting a conference call and live webcast today at 10:00 a.m. ET to discuss Fourth Quarter and Full Year 2007 Financial Results along with the contents of this press release.

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of Advanced Life Sciences' corporate website http://www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 888-713-4215 (domestic) or 617-213-4867 (international). Th
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014 A new Manhattan ... Decision Makers 2014, finds that members of ... care organizations (MCOs) and pharmacy benefits managers (PBMs) ... information.  A majority of formulary decision makers report ... during the formulary decision making process today than ...
(Date:7/14/2014)... July 14, 2014  Clinicians at a leading ... have become the first in the country to ... using an upgraded Clinac® medical linear accelerator from ... been enhanced with High Intensity Mode dose delivery ... Institute to shorten treatment times and deliver stereotactic ...
(Date:7/14/2014)... FAIRHOPE, Ala. , July 14, 2014  Patients ... of patients as Express Scripts and other major pharmacy ... coverage. The cuts will directly impact millions of patients ... of medical conditions, including persistent pain from cancer, diabetes ... will begin notifying some patients on July 15. ...
Breaking Medicine Technology:Digital Resources Play Critical Role in Formulary Decision Making 2Digital Resources Play Critical Role in Formulary Decision Making 3Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 2Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4
... WASHINGTON, Nov. 20 Pharmaceutical,researchers are testing 92 ... related conditions, according to a report released today ... December,1 marks the 20th anniversary of "World AIDS ... the 1988 World Summit of Ministers of Health ...
... in Non-Small Cell Lung Cancer Expected to Inform ... for Experimental Cancer Treatment, MOUNTAIN VIEW, Calif., ... a leading provider of software,strategic consulting, and regulatory ... its Strategic Consulting Services Group,is using a quantitative ...
Cached Medicine Technology:92 Medicines and Vaccines now in Development for HIV/AIDS 292 Medicines and Vaccines now in Development for HIV/AIDS 3Pharsight Uses FDA Disease Model to Support Oncology Drug Development 2Pharsight Uses FDA Disease Model to Support Oncology Drug Development 3
(Date:7/14/2014)... Europe’s market for cardiac surgery devices ... by 2020, with the transcatheter heart valve devices sector ... transcatheter mitral valve repair (TMVR) segments) fuelling this growth. ... ?urrently the only THVI product on the market. However, ... and are anticipated to get CE approval by end-2020. ...
(Date:7/14/2014)... Since the announcement of the merger to form AAG HealthGAINS ... has been traveling to our network of facilities nationwide to ... our proprietary Maximum Sexual Performance Program for men and women. ... location on July 22nd, AAG Health NYC, 65 Broadway, Suite ... train our staff, and be on hand to answer patient ...
(Date:7/14/2014)... The North America Biostimulant Market report defines and ... and forecast of revenue. The biostimulants market in North ... in 2013 to $490.1 million by 2018, at a ... through the TOC of the North America Biostimulant Market ... provided. This also provides a glimpse of the segmentation ...
(Date:7/14/2014)... 14, 2014 Employers looking to ... employees with more benefit options must understand how ... online marketplaces, are the future of employee benefits. ... Jersey (Horizon BCBSNJ) is offering a free webinar, ... Offering More Options, to demonstrate how HorizonSelect, its ...
(Date:7/14/2014)... Continuing a steady trend of growth ... the heels of first-quarter success with Orange Regional Medical ... company founded by CEO and President Dr. Virginia Feldman ... three new members. Robert Poltenovage has joined ... John Steele, LPN and Angelica D’Amico have joined the ...
Breaking Medicine News(10 mins):Health News:Europe Cardiac Surgery Device Market Value to Go Beyond USD 3.4 Bn by 2020, According to iData Research Study Available at MarketPublishers.com 2Health News:Europe Cardiac Surgery Device Market Value to Go Beyond USD 3.4 Bn by 2020, According to iData Research Study Available at MarketPublishers.com 3Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 2Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 3Health News:No Cost Employer Webinar to Demonstrate How Private Exchanges Can Lower Benefit Costs While Increasing Options for Employees 2Health News:Nexus Health Resources Continues Growth, Outstanding Health Care Coordination With Addition of Three New Team Members 2
... carcinoma in situDCISwho later develop invasive breast cancer in ... from breast cancer than those who do not develop ... 11 in the Journal of the National Cancer ... have compared breast conserving surgery (lumpectomy) to mastectomy and ...
... , FRIDAY, March 11 (HealthDay News) -- Taking ... but mostly in people at increased risk for the ... in their blood, according to a new study. ... or other nonsteroidal anti-inflammatory drugs (NSAIDs) have a reduced ...
... March 11 (HealthDay News) -- Watching your team win a ... be thrilling, but there may be a drawback: aggressive, testosterone-fueled ... found that traffic deaths at the game site and the ... game is over. Researchers at North Carolina State University ...
... are a burning issue. A straightforward guide to a closer understanding ... 2011). The Dose Makes the Poison: A Plain-Language Guide to Toxicology, ... leads to a distortion in many people,s conceptions of toxins and ... We are exposed to media reports on a daily basis of ...
... DETROIT Theories have long proposed that testosterone influences ... a recent study at Wayne State University give a ... mating behavior, and how testosterone is associated with dominance ... of an attractive woman. The study engaged ...
... causes AIDS invades human immune cells and causes ... can then infect new cells. A research team led ... Priv.-Doz. Dr. Barbara Mller of Heidelberg University Hospital have ... infected cell in virion release, and discovered that the ...
Cached Medicine News:Health News:DCIS patients who get invasive breast cancer have higher mortality 2Health News:Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People 2Health News:Fans of Winning Teams Linked to Fatal Crashes 2Health News:'The Dose Makes the Poison: A Plain-Language Guide to Toxicology,' 3rd Edition 2Health News:Wayne State study links testosterone with men's ability to 'woo' potential mates 2Health News:Pushing HIV out the door: How host factors aid in the release of HIV particles 2
LCD monitors....
This monitor is designed specifically for medical applications and is UL2601-1 listed....
Standard arthroscope with telescope (4 mm) for large joints....
A lower cost alternative to the flagship A3, the A1 retains the essential characteristics of high quality image, simplicity of operation and reliability....
Medicine Products: